Innostar appoints Dr. Sean Xiaochun Chen as CSO

文摘 2024-11-05 12:06 上海

SHANGHAI, 5 November 2024 - Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar) has officially announced the appointment of Dr. Sean Xiaochun Chen as Chief Scientific Officer (CSO) reporting to Dr. Yan Chang, President of InnoStar. Dr. Chen will lead and drive InnoStar's technological development and international market expansion in the field of non-clinical toxicology, contributing to InnoStar's growth on a global scale.

Dr. Sean Xiaochun Chen

Chief Scientific Officer

of Shanghai InnoStar

Bio-tech Co., Ltd.

Dr. Chen is a senior pharmacology and toxicology expert with over 20 years of experience in new drug discovery and development research. He served as a senior non-clinical review expert at the US Food and Drug Administration (FDA), working for over 8 years in the FDA's Center for New Drug Evaluation (CDER/OND) and Center for Biological Products Evaluation (CBER/OTP). During this time, Dr. Chen was responsible for the oversight of clinical research and marketing applications for small molecules, macromolecules, cell therapy, gene therapy, live organisms, and combination products, and participated in the approval of hundreds of Investigational New Drug applications and more than ten NDA/BLA marketing applications. Dr. Chen has demonstrated outstanding leadership and innovation during his tenure at the FDA. He not only provides valuable advice and guidance to companies on experimental design, data interpretation and product development strategies, but also provides pioneering regulatory recommendations and solutions for highly complex innovative products where precedents and guidance are lacking. In addition, Dr. Chen serves on several FDA subcommittees, consults on internal reviews, and participates in the drafting and development of several industry guidelines.

Dr. Chen received his Ph.D. in biomedical engineering from Zhejiang University. After completing his postdoctoral research at the Johns Hopkins University School of Medicine, he served as an Assistant Professor at the Center for Stem Cell Biology and Regenerative Medicine, University of Maryland School of Medicine, focusing on the discovery and development of innovative drugs. His research team has discovered several novel anti-leukemia and anti-infective drug candidates, one of which is currently in non-clinical development for the treatment of leukemia.

Dr. Chen

I'm incredibly grateful to InnoStar for trusting me and giving me this opportunity. It's a real honor to be part of such a professional team. I'm looking forward to working with my InnoStar colleagues on this platform to push the boundaries of scientific research and innovation in our society. I'm also committed to driving InnoStar's international expansion and strategic partnerships, accelerating research translation and project growth, and delivering first-class, efficient services to our clients. I'm excited about the future and hope that InnoStar will grow with me.

Dr. Chang Yan, President of InnoStar, extended a warm welcome to Dr. Chen Xiaochun and expressed confidence that his appointment will infuse the company with new vigor and momentum. InnoStar will continue to adhere to its core vision of 'Specializing in R&D Services and Empowering the Healthcare Industry' and is committed to providing customers with enhanced quality services and more efficient solutions, while also promoting the flourishing global biopharmaceutical industry.

从非临床到临床转化的一站式服务

上海益诺思生物技术股份有限公司成立于2010年，是国药集团下属中国医药工业研究总院有限公司的控股子公司。秉承“科学引领、质量唯先、诚信敬业、合作共赢”的核心价值观，以创新促发展、以质量求生存、以信誉赢客户、以管理创效益，公司先后通过NMPA的GLP认证、美国FDA的GLP检查、OECD的GLP认证，AAALAC认证及美国病理学会的CAP认证等，是一家专业的提供生物医药非临床研究服务为主的综合研发服务（CRO）企业。业务范围覆盖早期成药性评价、非临床药效学研究、非临床药代动力学研究、非临床安全性评价研究、临床生物样本分析、生物标志物与转化研究等领域。公司于2024年9月3日在上海证券交易所科创板成功上市（股票简称：益诺思，股票代码：688710）。

http://mp.weixin.qq.com/s?__biz=MzA5ODY0MDk2Ng==&mid=2247509730&idx=3&sn=5293adcbdd00b8ab2cc31613975156aa

益诺思Marketing

上海益诺思生物技术股份有限公司（股票代码：688710）成立于2010年，是国药集团下属中国医药工业研究总院有限公司的控股子公司。秉承 “科学引领、质量唯先、诚信敬业、合作共赢 ”的核心价值观。

最新文章

益诺思助力艾赛普生物全球首个泛肿瘤靶向显像剂获FDA IND

一问益答｜对话干细胞产业链生态，探索干细胞产品发展之路（下）

会议邀请 | 益诺思邀您共赴深圳，相聚科兴制药医药研究院2024年抗体药物开发技术创新论坛

合作共赢！益诺思祝贺辉大基因HG202眼科基因治疗药物IND获得FDA批准

海外会议｜益诺思邀您相聚ACT 2024 Annual Meeting

今日直播｜α核素，RDC... 从非临床到临床，探索放药研发新技术新路径

会议邀请 | 益诺思邀您共赴深圳，相聚深圳湾实验室靶向蛋白降解大会

活动预告｜缤纷11月，精彩活动汇聚一堂！

上海益诺思生物技术股份有限公司任命陈啸春博士为首席科学官

直播讲座｜α核素，RDC... 从非临床到临床，探索放药研发新技术新路径

Innostar appoints Dr. Sean Xiaochun Chen as CSO

施婧博士受邀出席2024年中国药学会医药生物分析学术年会

益诺思深圳通过GLP增项检查并获得《药物GLP认证证书》

【强强联合】VIQU核药CXO联盟邀您上海赴约，携手共促核药发展！

会议邀请 | 益诺思邀您共赴深圳，相聚SMART Symposium 靶向蛋白降解：从基础研究到临床应用研讨会

一期一会 | BD+资本天团大湾区首届BIO-CEO特训营启动

PBMC人源化小鼠模型：免疫治疗的得力助手

创新突破全球首个！益诺思助力艾尔普再生医学新一代细胞创新药双报双批

一问益答｜mRNA治疗性肿瘤疫苗——临床生物分析挑战与解决方案

益诺思与博腾股份达成战略合作

InnoStar Signed Strategic Partnership with Porton

今晚直播｜mRNA治疗性肿瘤疫苗——临床生物分析挑战与解决方案

QWBA解决方案：助您快速得到可定量的精细的药物组织分布数据

益诺思与复容投资战略合作仪式成功举行！

直播讲座｜mRNA治疗性肿瘤疫苗——临床生物分析挑战与解决方案

喜报！益诺思上海、益诺思南通顺利通过匈牙利OECD GLP认证

一问益答｜对话干细胞疗法，展望糖尿病治疗新篇章（上）

回顾九月精彩瞬间，共启行业新篇章

全球首个！益诺思助力瑞风生物眼科Usher综合征新药获批美国IND

海外会议｜益诺思邀您相聚22nd San Diego Biopharma Conference

今日直播｜对话干细胞疗法，展望糖尿病治疗新篇章

会议邀请 | 益诺思邀您共赴上海，相聚2024中国医药决策者峰会暨第四届医药魔方开放日

益平台 | ⁸⁹Zr标记的干细胞活体组织分布研究

再度蝉联！益诺思荣膺“最具成长性CXO企业TOP10”

直播讲座｜对话干细胞疗法，展望糖尿病治疗新篇章

会议邀请 | 益诺思邀您共赴沈阳，相聚2024年国际基因组学大会眼科大会

国内首款！益诺思助力中国生物上海公司MVA株猴痘疫苗获批临床

益诺思助力先声再明合成致死新靶点候选药物PoIθ抑制剂获批临床

益诺思毒理事业部副总经理魏丽萍受邀出席CGLTS2024细胞与基因免疫治疗北京亦庄峰会

媒体视角 | 夯实核心竞争优势益诺思总裁常艳：深耕创新药非临床研究服务领域

媒体视角 | 益诺思上市，科创板“添丁”

媒体视角 | CRO央企上市第一股来了！上市首日涨逾40%

2024益诺思品牌活动圆满落幕

CRO央企上市第一股益诺思(688710) 科创板成功上市

八月华彩瞬间，续写夏日华章

今日直播｜肿瘤免疫新赛道-新型肿瘤疫苗的安评策略分析

基因治疗与小核酸药物论坛暨益诺思与派真生物战略合作签约仪式在北京成功举办！

今日活动！基因治疗与小核酸药物论坛·北京站

会议邀请｜益诺思邀您相聚BIO HK 2024

直播讲座｜肿瘤免疫新赛道-新型肿瘤疫苗的安评策略分析

分类

时事

民生

政务

教育

文化

科技

财富

体娱

健康

情感

旅行

百科

职场

楼市

企业

乐活

学术

汽车

时尚

创业

美食

幽默

美体

文摘

原创标签

时事社会财经军事教育体育科技汽车科学房产搞笑综艺明星音乐动漫游戏时尚健康旅游美食生活摄影宠物职场育儿情感小说曲艺文化历史三农文学娱乐电影视频图片新闻宗教电视剧纪录片广告创意壁纸头像心灵鸡汤星座命理教育培训艺术文化金融财经健康医疗美妆时尚餐饮美食母婴育儿社会新闻工业农业时事政治星座占卜幽默笑话独立短篇连载作品文化历史科技互联网

发布位置

广东北京山东江苏河南浙江山西福建河北上海四川陕西湖南安徽湖北内蒙古江西云南广西甘肃辽宁黑龙江贵州新疆重庆吉林天津海南青海宁夏西藏香港澳门台湾美国加拿大澳大利亚日本新加坡英国西班牙新西兰韩国泰国法国德国意大利缅甸菲律宾马来西亚越南荷兰柬埔寨俄罗斯巴西智利卢森堡芬兰瑞典比利时瑞士土耳其斐济挪威朝鲜尼日利亚阿根廷匈牙利爱尔兰印度老挝葡萄牙乌克兰印度尼西亚哈萨克斯坦塔吉克斯坦希腊南非蒙古奥地利肯尼亚加纳丹麦津巴布韦埃及坦桑尼亚捷克阿联酋安哥拉